Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. (Q38259206)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Thomas Behrens

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

9

Wassim Kassouf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

6

Molly A Ingersoll

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1

Ashish M Kamat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

10

H Barton Grossman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

8

Bas van Rhijn

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

13

Peter J Goebell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

John A Taylor

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

M' Liss A Hudson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Beate Pesch

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Tilmann Todenhöfer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Ashish Chandra

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Juan Palou

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Marta Sanchez-Carbayo

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Bernd J Schmitz-Dräger

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

11 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

1069-1077

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25306288%20AND%20SRC:MED&resulttype=core&format=json

Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Urine markers for bladder cancer surveillance: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

p53 immunohistochemistry in bladder cancer--a new approach to an old question

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Immunocytology in the assessment of patients with asymptomatic hematuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer tr

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Biomarker research with prospective study designs for the early detection of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

The FGFR3 mutation is related to favorable pT1 bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Individual risk assessment in bladder cancer patients based on a multi-marker panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Delay and survival in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017

Delays in diagnosis and bladder cancer mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.017